Selective expansion of memory CD4+ T cells by mitogenic human CD28 generates inflammatory cytokines and regulatory T cells

European Journal of Immunology

Volumn 38, Issue 6, 2008, Pages 1522-1532

  Singh, Manisha ^a   Basu, Sreemanti ^a   Camell, Christina ^a   Couturier, Jacob ^a   Nudelman, Rodolfo J ^a   Medina, Miguel A ^a   Rodgers, John R ^a   Lewis, Dorothy E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Costimulation; Human T cells; Inflammation; Regulatory T cells; T cell activation

Indexed keywords

CD28 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; ANDROSTANE DERIVATIVE; CD45 ANTIGEN; ENZYME INHIBITOR; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE INHIBITOR; WORTMANNIN;

ANTIGEN PURIFICATION; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL SELECTION; CONTROLLED STUDY; CROSS LINKING; CYTOKINE PRODUCTION; EX VIVO STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INFLAMMATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MEMORY CELL; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ADULT; CELL DIFFERENTIATION; CELL PROLIFERATION; COCULTURE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MONONUCLEAR CELL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; ANDROSTADIENES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD45; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOKINES; ENZYME INHIBITORS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; PHOSPHODIESTERASE INHIBITORS; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 49649117477     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200737929     Document Type: Article

References (44)

1. Bretscher, P. A., A two-step, two-signal model for the primary activation of precursor helper T cells. Proc. Natl. Acad. Sci. USA 1999. 96: 185-190.
2. Siefken, R., Kurrle, R. and Schwinzer, R., CD28-mediated activation of resting human T cells without costimulation of the CD3/TCR complex. Cell. Immunol. 1997. 176: 59-65.
3. Siefken, R., Klein-Hessling, S., Serfling, E., Kurrle, R. and Schwinzer, R., A CD28-associated signaling pathway leading to cytokine gene transcription and T cell proliferation without TCR engagement. J. Immunol. 1998. 161: 1645-1651.
4. Dennehy, K. M., Elias, F., Na, S. Y., Fischer, K. D., Hunig, T. and Luhder, F., Mitogenic CD28 signals require the exchange factor Vav1 to enhance TCR signaling at the SLP-76-Vav-Itk signalosome. J. Immunol. 2007. 178: 1363-1371.
5. Tacke, M., Hanke, G., Hanke, T. and Hunig, T., CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: Evidence for functionally distinct forms of CD28. Eur. J. Immunol. 1997. 27: 239-247.
6. Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C. H., Hanke, T. et al., Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J. Exp. Med. 2005. 202: 445-455.
7. reg cells in the absence of T-cell receptor stimulation. Immunology 2006. 119: 441-450.
8. + regulatory T cells. Autoimmun. Rev. 2006. 5: 40-45.
9. Evans, E. J., Esnouf, R.M., Manso-Sancho, R., Gilbert, R. J., James, J. R., Yu, C., Fennelly, J. A. et al., Crystal structure of a soluble CD28-Fab complex. Nat. Immunol. 2005. 6: 271-279.
10. Rodriguez-Palmero, M., Franch, A., Castell, M., Pelegri, C., Perez-Cano, F. J., Kleinschnitz, C., Stoll, G. et al., Effective treatment of adjuvant arthritis with a stimulatory CD28-specific monoclonal antibody. J. Rheumatol. 2006. 33: 110-118.
11. Schmidt, J., Elflein, K., Stienekemeier, M., Rodriguez-Palmero, M., Schneider, C., Toyka, K. V., Gold, R. and Hunig, T., Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies. J. Neuroimmunol. 2003. 140: 143-152.
12. Tischner, D., Weishaupt, A., van den Brandt, J., Muller, N., Beyersdorf, N., Ip, C. W., Toyka, K. V. et al., Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. Brain 2006. 129: 2635-2647.
13. Urakami, H., Ostanin, D. V., Hunig, T. and Grisham, M. B., Combination of donor-specific blood transfusion with anti-CD28 antibody synergizes to prolong graft survival in rat liver transplantation. Transplant. Proc. 2006. 38: 3244-3246.
14. Duff, G., Expert Scientific Group [ESG] on Phase One Clinical Trials, Final report. Stationery Office, Norwich, UK, 30 November 2006 (http://www.dh.gov.uk/prod_consum@dh/groups/dh_digitalassets/ @dh/@en/documents/digitalasset/dh_073165.pdf)
15. Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D. and Panoskaltsis, N., Cytokine stormin a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 2006. 355: 1018-1028.
16. Corry, D. B. and Lewis, D. E., Cytokine storm and an anti-CD28 monoclonal antibody. N. Engl. J. Med. 2006. 355: 2592.
17. Ohresser, M., Olive, D., Vanhove, B. and Watier, H., Risk in drug trials. Lancet 2006. 368: 2205-2206.
18. Lin CH, H. T., Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur. J. Immunol. 2003. 33: 626-638.
19. -T cells. J. Clin. Invest 2003. 112: 1437-1443.
20. Stebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y. et al., "Cytokine storm" in the Phase I trial of monoclonal antibody TGN1412: Better understanding the causes to improve preclinical testing of immunotherapeutics. J. Immunol. 2007. 179: 3325-3331.
21. Sester, U., Wabnitz, G. H., Kirchgessner, H. and Samstag, Y., Ras/ P13kinase/cofilin-independent activation of human CD45RA(+) and CD45RO(+) T cells by superagonistic CD28 stimulation. Eur. J. Immunol. 2007. 37: 2881-2891.
22. -/- mice. Blood 2006. 108: 238-245.
23. + regulatory T cell function. J. Exp. Med. 2002. 196: 851-857.
24. - T cells by T cell receptor stimulation is TGF-beta-dependent but does not confer a regulatory phenotype. Blood 2007. 110: 2983-2990.
25. Frauwirth, K. A., Riley, J. L., Harris, M. H., Parry, R. V., Rathmell, J. C., Plas, D. R., Elstrom, R. L. et al., The CD28 signaling pathway regulates glucose metabolism. Immunity 2002. 16: 769-777.
26. Hanawa, H., Ma, Y., Mikolajczak, S. A., Charles, M. L., Yoshida, T., Yoshida, R., Strathdee, C. A. et al., A novel costimulatory signaling in human T lymphocytes by a splice variant of CD28. Blood 2002. 99: 2138-2145.
27. Okkenhaug, K., Patton, D. T., Bilancio, A., Garcon, F., Rowan, W. C. and Vanhaesebroeck, B., The p110δ isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J. Immunol. 2006. 177: 5122-5128.
28. + regulatory T cells. J. Immunol. 2006. 177: 6598-6602.
29. Mirenda, V., Jarmin, S. J., David, R., Dyson, J., Scott, D., Gu, Y., Lechler, R. I. et al., Physiologic and aberrant regulation of memory T-cell trafficking by the costimulatory molecule CD28. Blood 2007. 109: 2968-2977.
30. Liu, Y., Jiang, N., Wu, J., Dai, W. and Rosenblum, J. S., Polo-like kinases inhibited by wortmannin. Labeling site and downstream effects. J. Biol. Chem. 2007. 282: 2505-2511.
31. Liu, Y., Shreder, K. R., Gai, W., Corral, S., Ferris, D. K. and Rosenblum, J. S., Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem. Biol. 2005. 12: 99-107.
32. + T cells and Th2 effector cells. J. Immunol. 1999. 162: 7110-7119.
33. Lewis, D. E., Merched-Sauvage, M., Goronzy, J. J., Weyand, C. M. and Vallejo, A. N., Tumor necrosis factor-alpha and CD80 modulate CD28 expression through a similar mechanism of T-cell receptor-independent inhibition of transcription. J. Biol. Chem. 2004. 279: 29130-29138.
34. Raab, M., Pfister, S. and Rudd, C. E., CD28 signaling via VAV/ SLP-76 adaptors. Regulation of cytokine transcription independent of TCR ligation. Immunity 2001. 15: 921-933.
35. Rudd, C. E. and Raab, M., Independent CD28 signaling via VAV and SLP-76: A model for in trans costimulation. Immunol. Rev. 2003. 192: 32-41.
36. Knight, Z. A. and Shokat, K. M., Features of selective kinase inhibitors. Chem. Biol. 2005. 12: 621-637.
37. + T cells. J. Immunol. 2000. 164: 265-272.
38. Dutton RW, B. L., Swain, SL, T cell memory. Annu. Rev. Immunol. 1998. 16: 201-223.
39. Ekkens, M. J., Liu, Z., Liu, Q., Foster, A., Whitmire, J., Pesce, J., Sharpe, A. H. et al., Memory Th2 effector cells can develop in the absence of B7-1/B7-2, CD28 interactions, and effector Th cells after priming with an intestinal nematode parasite. J. Immunol. 2002. 168: 6344-6351.
40. Suresh, M., Whitmire, J. K., Harrington, L. E., Larsen, C. P., Pearson, T. C., Altman, J. D. and Ahmed, R., Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory. J. Immunol. 2001. 167: 5565-5573.
41. Croft, M., Bradley, L. M. and Swain, S. L., Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J. Immunol. 1994. 152: 2675-2685.
42. Ndejembi, M. P., Teijaro, J. R., Patke, D. S., Bingaman, A. W., Chandok, M. R., Azimzadeh, A., Nadler, S. G. and Farber, D. L., Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. J. Immunol. 2006. 177: 7698-7706.
43. + T cells. Eur. J. Immunol. 2007. 37: 129-138.
44. Romano, M. F., Bisogni, R., Lamberti, A., Turco, M. C., Petrella, A., Tassone, P., Van Lier, R. et al., Regulation of NFκB nuclear activity in peripheral blood mononuclear cells: Role of CD28 antigen. Cell. Immunol. 1994. 156: 371-377.